This site is intended for Healthcare Professionals only.

ITV invests in pain relief brand Flarin

Date:

Share post:

ITV on Tuesday (Aug 15) said it had agreed to invest in pain relief brand Flarin Holdings Ltd, making it the British broadcaster’s first consumer healthcare investment.

The company has agreed to subscribe for £2 million worth of shares in Flarin, with an option to subscribe for two more tranches of 1.5 million pounds each.

In return, Flarin would get advertising space across ITV’s channels and ITVX.

ITV said its investment will “help Flarin build mass market brand awareness by bringing the brand to millions of consumers via ITV platforms. This will be a step change in the size of the campaign and the approach to scaling the Flarin brand to date.”

Director of ITV AdVentures, Sheena Amin, said: “It’s fantastic to be announcing our latest Media for Equity investment into Flarin. With its innovative and patented lipid technology, Flarin offers many unique benefits to those suffering from joint and muscular pain compared to any other product on the market. Flarin is already one of the fastest growing analgesics in the market and I am confident that we will see the company grow to new heights following a brand building campaign across ITV.”

Flarin was launched in the UK in 2018 as a pharmacy only product, but in 2020 its distribution was expanded into grocery and other retail outlets. Patents for the Flarin formulation are also held in 26 other countries.

It’s claimed that Flarin is “the first and only OTC lipid-formulated ibuprofen clinically proven to relieve flaring joint pain”. Flarin’s patented lipid technology is based on a complex manufacturing process which involves heating and dissolving specific pharmaceutical grade lipids, ibuprofen and other excipients together in a process lasting three days. It encases ibuprofen in lipids which help it to travel through the stomach and into the small intestine where it is absorbed.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue December 2023

Related articles

RPS workforce wellbeing survey: 86% of pharmacists are at high risk of burnout

Inadequate staffing is identified as the main factor contributing to poor mental health and wellbeing. The Royal Pharmaceutical...

Chelmsford drug dealer operating as ‘unlicensed chemist’ jailed for six years

Police discovered more than 50,000 pills and tablets of varying types at his residence on Wood Street in...

RPS and PDA respond to DHSC consultation on pharmacy supervision: Read here

Supervision by pharmacy technicians at hospital aseptic facilities should be considered in an entirely separate consultation, PDA said....

Over 100 medicines are currently in short supply, warns BGMA

Reducing disruptions to the movement of medicines around the world is “absolutely critical” for maintaining supply resilience in...